ArticleJournal of perinatology : official journal of the California Perinatal Association2016
An opportunistic study evaluating pharmacokinetics of sildenafil for the treatment of pulmonary hypertension in infants.
Article in Journal of perinatology : official journal of the California Perinatal Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 12 citations in OpenAlex.
- Prophylactic Sildenafil in Preterm Infants at Risk of Bronchopulmonary Dysplasia: A Pilot Randomized, Double-Blinded, Placebo-Controlled Trial.Clinical drug investigation · 2019Trial
- Development of a population pharmacokinetic model using combined paediatric and adult data for four pulmonary arterial hypertension drugs.British journal of clinical pharmacology · 2026Article
- Dexmedetomidine use in Infants undergoing Cooling due to neonatal Encephalopathy (DICE trial): safety and pharmacokinetics.Pediatric research · 2026Article
- Population pharmacokinetic analysis of sildenafil in term and preterm infants with pulmonary arterial hypertension.Scientific reports · 2022Article
- Update on the use of sildenafil in neonatal pulmonary hypertension: a narrative review of the history, current administration, and future directions.Translational pediatrics · 2021Review
- Methodologic Progress Note: Opportunistic Sampling for Pharmacology Studies in Hospitalized Children.Journal of hospital medicine · 2021Article
- Dexmedetomidine Use in Infants Undergoing Cooling Due to Neonatal Encephalopathy (DICE Trial): A Randomized Controlled Trial: Background, Aims and Study Protocol.Frontiers in pain research (Lausanne, Switzerland) · 2021Article
- Population pharmacokinetics of sildenafil in extremely premature infants.British journal of clinical pharmacology · 2019Article
- Neonatal Therapeutics: Considerations for Dosing.American journal of perinatology · 2019Review
- Association between oral sildenafil dosing, predicted exposure, and systemic hypotension in hospitalised infants.Cardiology in the young · 2018Article
- Clinical Pharmacology Studies in Critically Ill Children.Pharmaceutical research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveThe objective of this study is to assess sildenafil and N-desmethyl sildenafil (DMS) exposure in infants receiving sildenafil for the treatment of pulmonary hypertension (PH). STUDY
designData were collected from six infants receiving sildenafil for the treatment of PH and plasma samples were collected at the time of routine laboratory blood draws. The echocardiography results were assessed for improvement in right ventricular (RV) hypertension following sildenafil treatment.
resultThe median (range) sildenafil and DMS concentrations were 27.4 ng ml(-1) (2.6 to 434.0) and 105.5 ng ml(-1) (3.6 to 314.0), respectively. The median metabolite-to-parent ratio was higher in infants receiving co-medications that can induce cytochrome P450 (CYP) enzymes (5.2 vs 0.7). The echocardiography results showed improvement in RV hypertension for the majority of infants (5/6).
conclusionThe concentrations of sildenafil and DMS were within the previously observed ranges. Our results suggest that caution may be warranted when CYP-related co-medications are administered during sildenafil treatment for PH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.